Taosheng Chen Selected Research

kenpaullone

1/2018	CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss.
1/2018	Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss.
11/2008	Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Taosheng Chen Research Topics

Disease

34	Neoplasms (Cancer) 01/2022 - 05/2009
6	Alveolar Rhabdomyosarcoma 01/2021 - 11/2009
5	Leukemia 11/2021 - 11/2017
5	Carcinoma (Carcinomatosis) 01/2017 - 11/2008
4	Drug-Related Side Effects and Adverse Reactions 11/2021 - 08/2009
4	Hearing Loss (Hearing Impairment) 12/2020 - 01/2016
4	Neoplasm Metastasis (Metastasis) 11/2013 - 02/2011
3	Neuroblastoma 11/2021 - 01/2017
3	Carcinogenesis 01/2021 - 04/2014
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 09/2015
3	Ototoxicity 12/2020 - 01/2016
2	Cardiotoxicity 11/2021 - 01/2021
2	Inflammation (Inflammations) 11/2021 - 08/2009
2	Anemia 01/2021 - 01/2020
2	Breast Neoplasms (Breast Cancer) 01/2021 - 05/2009
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 01/2020
2	Noise-Induced Hearing Loss (Acoustic Trauma) 12/2020 - 01/2018
2	Metabolic Diseases (Metabolic Disease) 05/2015 - 07/2013
2	Colonic Neoplasms (Colon Cancer) 04/2014 - 11/2013
2	Bone Diseases (Bone Disease) 05/2009 - 08/2006
1	Pathologic Processes 01/2022
1	Sarcoma (Soft Tissue Sarcoma) 01/2022
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2021
1	Ischemia 01/2021
1	Hypoxia (Hypoxemia) 01/2021
1	Glioma (Gliomas) 01/2021
1	Melanoma (Melanoma, Malignant) 10/2020
1	Infections 01/2020
1	Acute Kidney Injury (Acute Renal Failure) 01/2020
1	Vitamin B 6 Deficiency (Pyridoxine Deficiency) 01/2020
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2020
1	Pellagra 01/2020
1	Ischemic Stroke 01/2020
1	Acute Intermittent Porphyria (Porphyria, Acute) 01/2020
1	Pulmonary Embolism 01/2020
1	Disease Progression 12/2019
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019
1	Hepatocellular Carcinoma (Hepatoma) 01/2019
1	Medulloblastoma 01/2019

Drug/Important Bio-Agent (IBA)

13	Pharmaceutical PreparationsIBA 11/2021 - 08/2009
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2009
8	Transcription Factors (Transcription Factor)IBA 01/2022 - 04/2011
8	Pregnane X ReceptorIBA 01/2020 - 11/2008
6	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2022 - 04/2014
6	Cytochrome P-450 CYP3AIBA 01/2020 - 11/2008
5	XenobioticsIBA 12/2017 - 04/2014
4	LigandsIBA 01/2021 - 07/2013
4	Cisplatin (Platino)FDA LinkGeneric 12/2020 - 01/2016
4	EnzymesIBA 12/2019 - 08/2009
3	kenpaulloneIBA 01/2018 - 11/2008
2	Histone DemethylasesIBA 01/2021 - 01/2017
2	Anti-Bacterial Agents (Antibiotics)IBA 12/2020 - 01/2020
2	Phosphotransferases (Kinase)IBA 12/2020 - 01/2018
2	Isoniazid (Ftivazide)FDA LinkGeneric 01/2020 - 01/2019
2	Cyclin-Dependent Kinase 2IBA 01/2018 - 11/2008
2	Protein Isoforms (Isoforms)IBA 09/2017 - 09/2016
2	LuciferasesIBA 01/2017 - 01/2013
2	Orphan Nuclear ReceptorsIBA 01/2016 - 02/2015
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 06/2010 - 11/2008
1	ChromatinIBA 01/2022
1	snake venom protein C activatorIBA 12/2021
1	Topoisomerase I InhibitorsIBA 11/2021
1	CX 5461IBA 11/2021
1	RNA (Ribonucleic Acid)IBA 11/2021
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 11/2021
1	Oncogene Proteins (Oncogene Protein)IBA 01/2021
1	17- (dimethylaminoethylamino)- 17- demethoxygeldanamycinIBA 01/2021
1	ElonginIBA 01/2021
1	Proteolysis Targeting ChimeraIBA 01/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021
1	Vincristine (Oncovin)FDA LinkGeneric 01/2021
1	nilotinib FDA Link 01/2021
1	Calcium-Binding ProteinsIBA 01/2021
1	Proto-Oncogene Proteins B-rafIBA 12/2020
1	dabrafenibIBA 12/2020
1	Ligases (Synthetase)IBA 10/2020
1	AntigensIBA 10/2020
1	UbiquitinIBA 10/2020
1	Cytotoxins (Cytolysins)IBA 01/2020
1	Biological ProductsIBA 01/2020
1	ElectrolytesIBA 01/2020
1	Antitubercular AgentsIBA 01/2020
1	Antineoplastic Agents (Antineoplastics)IBA 01/2020
1	Adenosine Triphosphate (ATP)IBA 01/2020
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2020
1	Niacinamide (Nicotinamide)FDA LinkGeneric 01/2020
1	protoporphyrin IXIBA 01/2019
1	Messenger RNA (mRNA)IBA 01/2019
1	quisinostatIBA 01/2019
1	Vitamin B 6IBA 01/2019
1	Small Interfering RNA (siRNA)IBA 01/2019
1	Mutant Proteins (Protein, Mutant)IBA 01/2019
1	Histone Deacetylase InhibitorsIBA 01/2019
1	hydrazine (hydrazine dihydrochloride)IBA 01/2019
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2018

Therapy/Procedure

14	Therapeutics 11/2021 - 10/2010
6	Drug Therapy (Chemotherapy) 12/2020 - 11/2009
3	Immunotherapy 11/2021 - 01/2019
1	Aftercare (After-Treatment) 11/2021
1	Adjuvant Chemotherapy 01/2019